Thailand Digital Health & Telemedicine Market Intelligence
Thai digital health post-COVID. Telemedicine: Doctor Anywhere, MorDee, SeeDoctorNow. Hospital digital: BDMS, Bumrungrad, Samitivej. AI: Preceptra. Reimbursement still immature.
Key takeaways
- 1
Thai digital health accelerated post-COVID. MOPH telemedicine licensing framework rolled out 2020 under emergency provisions; partial permanence post-emergency.
- 2
Telemedicine platforms: Doctor Anywhere (Singapore-HQ Thai operations), MorDee (BDMS Samitivej app), SeeDoctorNow startup. Hospital-affiliated apps generally do better than pure-play due to consultation-fee, brand trust.
- 3
Hospital digital infrastructure: BDMS HealthCare suite, Bumrungrad B+, Samitivej app β patient portal, EMR access, appointment, telemedicine integrated.
- 4
AI diagnostics: Preceptra (Thai radiology AI startup, BDMS-backed) is the standout. Other AI tools largely from MNC hospital systems vendors.
- 5
Reimbursement structurally immature: telemedicine consultations partially reimbursed by SSO (Social Security), private insurers; NHSO UCS coverage limited. PDPA (Personal Data Protection Act) compliance, medical-data privacy emerging concern.
Executive summary
Thailand's digital health sector accelerated sharply post-COVID, building on MOPH telemedicine licensing rolled out 2020 under emergency public health provisions. Active user counts grew from < in 2020 to ~6- in 2024 across telemedicine, hospital apps, pharma e-commerce. The sector splits into five segments: telemedicine consultation (~ of activity), hospital, EMR digital infrastructure (~), AI diagnostic, radiology (~), pharma e-commerce, delivery (~), wellness, chronic-care apps (~).[, ]
Telemedicine: Doctor Anywhere (Singapore-HQ multinational with strong Thai presence) leads pure-play; MorDee (BDMS Samitivej-affiliated app) leads hospital-integrated; SeeDoctorNow, smaller startups fill mid-tier. Hospital-affiliated apps generally outperform pure-play due to fee-collection, brand-trust, integration with EMR, diagnostics, pharmacy, lab.[, ]
Hospital digital infrastructure: BDMS HealthCare suite, Bumrungrad B+, Samitivej app, various hospital-specific platforms. Patient portal, EMR access, appointment, telemedicine, lab, pharmacy in unified app. AI diagnostics: Preceptra (Thai radiology AI startup, BDMS-backed) is the standout local player; other AI from MNC hospital-systems vendors (Siemens Healthineers, GE, Philips, Aidoc). Reimbursement remains structurally immature β partial telemedicine reimbursement from SSO, private insurance; NHSO UCS coverage limited. PDPA compliance, medical-data privacy is a rising operational concern.[, , , ]
Thai digital health active user growth (millions, 2020-2024)
2020
Active users (M)
0.5
Context
Pre-COVID baseline
2021
Active users (M)
2.0
Context
COVID emergency telemedicine surge
2022
Active users (M)
3.5
Context
Post-emergency continued growth
2023
Active users (M)
5.0
Context
Hospital app, AI scaling
2024
Active users (M)
6.5
Context
Pharma e-com, chronic-care expansion
| Year | Active users (M) | Context |
|---|---|---|
| 2020 | 0.5 | Pre-COVID baseline |
| 2021 | 2.0 | COVID emergency telemedicine surge |
| 2022 | 3.5 | Post-emergency continued growth |
| 2023 | 5.0 | Hospital app, AI scaling |
| 2024 | 6.5 | Pharma e-com, chronic-care expansion |
Segment mix (% FY2024 activity)
Telemedicine consultation
Share %
Drivers
Doctor Anywhere, hospital apps
Hospital, EMR digital
Share %
Drivers
AI diagnostic, radiology
Share %
Drivers
Preceptra, MNC
Pharma e-com, delivery
Share %
Drivers
iTAX, Fascino, Pharmacist Online
Wellness, chronic-care apps
Share %
Drivers
Diabetes, cardio chronic
| Segment | Share % | Drivers |
|---|---|---|
| Telemedicine consultation | 35% | Doctor Anywhere, hospital apps |
| Hospital, EMR digital | 25% | BDMS, Bumrungrad, Samitivej |
| AI diagnostic, radiology | 15% | Preceptra, MNC |
| Pharma e-com, delivery | 15% | iTAX, Fascino, Pharmacist Online |
| Wellness, chronic-care apps | 10% | Diabetes, cardio chronic |
Analyst framing
Why this report
Unlock the full report
Need more than the web report? Ask for a scoped export or source appendix.
Every report keeps visible citations and source metadata. Terms.
Key figures
Selected anchors from the report evidence pack.
Telemedicine Registered Users in Thailand
MOPH Telemedicine Guidelines, NHSO Virtual Care Pilot reports, Doctor Anywhere corporate disclosures
NHSO Virtual-Care Reimbursement Budget
NHSO Annual Report and virtual-care pilot documentation, MOPH Digital Health Policy
BDMS Telehealth Consultation Volume
BDMS Annual Report, Hdcare platform disclosures, MOPH e-Health strategy reports
MOPH Smart Hospital Rollout Target
MOPH Digital Health Policy Framework, eHealth Thailand strategy documents, National Digital Economy and Society Commission
Doctor Anywhere Thailand Consultation Volume
Doctor Anywhere press releases and Series C investor documentation, APAC digital health analyst surveys
Related reports
Thailand Healthcare Services & Medical Tourism Market Intelligence
Thailand runs Asia's deepest medical-tourism franchise β 60+ JCI-accredited hospitals, ~3-4M medical-tourism visits generating USD 1.5-2B in receipts. BDMS (SET: BDMS) anchors at >THB 110B FY2024 across 50+ hospitals; Bumrungrad (SET: BH) runs >60% international-patient revenue mix. Public insurance (UCS ~47M, SSS ~15M) plus private, international cash-pay shape the payor mix. Physician supply at 0.9-1.0 per 1,000 is the binding workforce constraint on growth.
Open report β
Thailand Hospital Group Consolidation Deep Dive
Deep-dive into Thai hospital group consolidation. Listed hospital operators: BDMS (SET: BDMS, largest β Bumrungrad, Samitivej, BPH, 50+ hospital network), Bumrungrad International (SET: BH, direct listing), Bangkok Chain Hospital (SET: BCH β World Medical, WMC), Chularat (SET: CHG β eastern corridor, industrial-estate), Principal Healthcare (SET: PRINC β provincial consolidator), Thonburi Healthcare (SET: THG), Praram 9 (SET: PR9 β cardiac, oncology specialty), Ramkhamhaeng Hospital (SET: RAM β listed federation of Ramkhamhaeng-brand hospitals). M&A track record: BDMS roll-up of Samitivej, Paolo, BPH, regional provincial; PRINC provincial network consolidation; THG Thonburi expansion; BCH World Medical, WMC acquisitions. Drivers: aging Thai population (20%+ >65 by 2030), rising private-pay, SSO, UCS volume, medical tourism scale, international-insurer integration. EBITDA margins: urban tier-1 JCI-accredited ~30-40%; provincial tier-2 ~15-25%; rural tier-3 ~10-15%. Pillar Two (2025+), Thai Medical Council foreign-physician restriction, workforce cap shape economics.
Open report β
Thailand Medical Tourism Pricing & Economics Deep Dive
Deep-dive into Thailand's medical tourism pricing, payer mix, cross-border patient flows. 3-4M medical tourists/yr generating USD 1.5-2B receipts. Listed hospital operators: BDMS (SET: BDMS β Bumrungrad, Samitivej, BPH), Bangkok Chain Hospital (SET: BCH), Chularat (SET: CHG), Principal Healthcare (SET: PRINC), Thonburi Healthcare (SET: THG), Praram 9 (SET: PR9), plus Bumrungrad International direct. Procedure pricing: cosmetic USD 1.5-4k (vs USD 6-15k US), cardiac bypass USD 8-15k (vs USD 70-100k US), IVF USD 4-6k/cycle (vs USD 15-20k US). Cross-border flows: GCC (~30%) premium cardiac, oncology, rehab; CLMV (~24%) emergency, elective; China (~18%) cosmetic, anti-aging, reproductive; USA, Europe, Australia (~16%) cost-sensitive cardiac, orthopedic, cosmetic. Payers: self-pay ~70%, international insurers (Cigna Global, Bupa Global, GeoBlue, AXA Global), government contracts, employer plans. Thai Medical Council, MoPH regulate; TAT markets.
Open report β
Thailand Diagnostic Lab & Imaging Deep Dive
Deep-dive into Thai diagnostic lab, medical imaging ~THB 55-70B FY2024. Hospital-integrated clinical labs at Bumrungrad, Samitivej, Bangkok Hospital, Piyavate, Ramkhamhaeng, public university hospitals; specialist reference labs (N Health, Thyrocare, LabPlus, Professional Laboratory); medical imaging (X-ray, CT, MRI, PET-CT, ultrasound, nuclear); point-of-care, home-test kits, digital diagnostic. Equipment imported from Siemens Healthineers, GE HealthCare, Philips, Roche, Abbott, Sysmex, Hitachi. 2020-2022 COVID testing surge boosted revenue; post-COVID corporate wellness, health screening, medical tourism return drive recovery. Regulation: Thai FDA MDCD, MoPH NCD screening.
Open report β